A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage
of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.